Amgen submits denosumab BLA
Executive Summary
Amgen has submitted a BLA for its novel RANK ligand inhibitor denosumab for two indications: treatment and prevention of postmenopausal osteoporosis in women and bone loss in patients undergoing hormone ablation for either prostate or breast cancer. The filing, announced Dec. 18, is supported by two Phase III pivotal studies with fracture endpoints. Analysts have projected the twice-yearly injectable fully human monoclonal antibody could be worth as much as $2.4 billion worldwide by 2016, just in the PMO indication (1"The Pink Sheet" DAILY, July 29, 2008)
You may also be interested in...
Amgen’s Positive Denosumab Pivotal Trial Reduces Overhangs For Firm
Big biotech needs the potential $2.4 billion analysts estimate the bone-building drug could bring by 2016.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.